Tesamorelin (GHRH Analogue) | 2mg, 5mg, 10mg & 20mg
Technical Specifications
- Sequence: Trans-3-hexenoyl-[Tyr1]hGRF(1–44)NH2
- Chemical Name: Tesamorelin Acetate
- Format: Lyophilised Cake/Powder
- Purity: >99% (HPLC Verified)
- Target: GHRH Receptors (Anterior Pituitary)
- Mechanism: Selective reduction of Visceral Adipose Tissue (VAT)
- Half-Life: Extended (stabilised by N-terminal modification)
- Solubility: High (Aqueous)
- Solvent: Solvent not included (Sold Separately)
- Grade: Analytical Research Grade
Variant Breakdown
- 2mg & 5mg Vials: Standard research aliquots.
- 10mg Vial: High-Concentration Vial.
- 20mg Vial: Ultra-High Density.
- Vial Capacity: 3ml.
- Note: The 20mg vial contains a dense peptide "puck." It requires patience and proper technique to fully dissolve in just 3ml of solvent.
Peptide Overview
Tesamorelin is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) consisting of 44 amino acids with a trans-3-hexenoic acid group attached to the N-terminus.
This specific chemical modification prevents rapid enzymatic degradation, giving Tesamorelin a significantly longer half-life and higher potency than natural GHRH.
The "Visceral Fat" Specialist:
Tesamorelin is unique among secretagogues because it is the only peptide in its class with FDA approval (under the trade name Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy. Research indicates that it stimulates the pituitary to release endogenous Growth Hormone in a pulsatile manner, which preferentially targets deep adipose tissue stores and lowers triglyceride levels, without significantly altering glucose control (a common side effect of direct HGH administration).
Quality Assurance
This compound has undergone rigorous third-party analysis.
- HPLC Verified: Independent analysis confirms peptide purity exceeds 99%.
- Mass Spectrometry: Confirms the presence of the trans-3-hexenoic acid moiety, which is critical for its extended stability.
- TFA Removal: Processed via acetate exchange to ensure cellular viability.
Research Mechanism
In laboratory settings, Tesamorelin is utilised to investigate:
- Visceral Lipolysis: The mechanism by which pulsatile GH release triggers the oxidation of visceral adipose tissue (VAT) specifically.
- Metabolic Profile: Researching the reduction of triglycerides and the improvement of the lipid profile in metabolically compromised models.
- IGF-1 Modulation: Studies examining the sustainable elevation of Insulin-Like Growth Factor 1 (IGF-1) levels for anabolic support without pituitary desensitisation.
- Cognitive Function: Emerging research into the role of GHRH analogues in improving executive function and memory in mild cognitive impairment.
Safety and Handling
WARNING: This product is exclusively for laboratory research and in vitro use.
- Research Only: Not intended for human consumption, bodybuilding, or therapeutic use.
- Handling: Wear appropriate personal protective equipment (PPE).
Storage: Store lyophilised vials in a cool, dry place. For long-term preservation, freezing at -20°C is recommended.
Scientific References
New England Journal of Medicine (2010) – "Effects of tesamorelin on visceral fat and metabolic abnormalities in HIV-infected patients with abdominal lipohypertrophy." (The landmark FDA approval study).View Article
Clinical Interventions in Aging (2014) – "Tesamorelin: a review of its clinical potential in the treatment of HIV-associated lipodystrophy." View Article
Archives of Neurology (2012) – "Effects of GHRH on cognitive function in healthy older adults and in adults with mild cognitive impairment." (The key study on nootropic potential). View Article
PLoS One (2013) – "Safety and efficacy of tesamorelin in the reduction of excess visceral adipose tissue." View Article
